Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGS) EBIT (2020 - 2025)

Historic EBIT for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to -$3.3 million.

  • GeneDx Holdings' EBIT rose 5821.34% to -$3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year increase of 11728.0%. This contributed to the annual value of -$23.2 million for FY2024, which is 8714.64% up from last year.
  • As of Q3 2025, GeneDx Holdings' EBIT stood at -$3.3 million, which was up 5821.34% from $9.0 million recorded in Q2 2025.
  • Over the past 5 years, GeneDx Holdings' EBIT peaked at $9.0 million during Q2 2025, and registered a low of -$324.9 million during Q4 2022.
  • Its 5-year average for EBIT is -$69.3 million, with a median of -$45.4 million in 2021.
  • Its EBIT has fluctuated over the past 5 years, first crashed by 25787.93% in 2022, then surged by 18469.61% in 2025.
  • Quarter analysis of 5 years shows GeneDx Holdings' EBIT stood at -$115.8 million in 2021, then plummeted by 180.6% to -$324.9 million in 2022, then soared by 92.11% to -$25.6 million in 2023, then skyrocketed by 134.34% to $8.8 million in 2024, then crashed by 136.92% to -$3.3 million in 2025.
  • Its EBIT was -$3.3 million in Q3 2025, compared to $9.0 million in Q2 2025 and -$4.6 million in Q1 2025.